Global Sarcopenia Treatment Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product Type, Application, Route of Administration, Distribution Channel and Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Industry Forecast (2024 to 2029)

Updated On: June, 2024
ID: 14240
Pages: 150

Global Sarcopenia Treatment Market Size (2024 to 2029)

The global sarcopenia treatment market is expected to grow at a CAGR of 6% from 2024 to 2029 and the market size is predicted to be worth USD 424 million by 2029.

Current Scenario of the Global Sarcopenia Treatment Market

Sarcopenia is a condition that is related to the progressive Loss of Skeletal Muscles and strength, which can cause physical disability or even death if left untreated. It is generally caused by Aging, as it's seen mostly in aged patients and prolonged physical inactivity with poor nutrition is also associated with Sarcopenia as these two factors play a major role in Sarcopenia. Currently, as of 2023, there exists no cure for Sarcopenia, although the symptoms of Sarcopenia are treated with a combination of dietary supplements and nutrition to increase the quality of life of the Sarcopenia Patients

MARKET DRIVERS

The growing global aging population and increasing cases of malnutrition in developing countries majorly propel the growth of the global sarcopenia treatment market. Sarcopenia is mostly seen in the elderly and aged people. With an increase in the population of the elderly, the cases of Sarcopenia are rising in prevalence. An increase in cases will have a direct impact on the sarcopenia treatment market. The rapid adoption of sedentary lifestyles among the population is predicted to result in the increasing incidence of sarcopenia and contribute to the growth of the sarcopenia treatment market. The increasing prevalence of malnutrition and protein deficiency among the population of developing countries favours the global market growth. The rising awareness of the treatment options for sarcopenia and increasing awareness of the supplements and importance of proteins and vitamins further support the growth of the global sarcopenia treatment market.

MARKET RESTRAINTS

The high costs associated with the treatment options for sarcopenia are one of the key factors hampering the market growth. Sarcopenia is not curable, and the treatment needs to be continuous for it to be effective. This increases the recurring costs; protein supplements can be very expensive depending on the quality. The dietary supplements and proteins may not be the cause of Sarcopenia in the patient and the supplements are not proven to be completely effective either, combined with the high recurring costs of these medications are a major restraining factor for the sarcopenia treatment market. The exercises are proven to be more effective for Sarcopenia; regular exercise was found to restore mitochondria homeostasis and dampen inflammatory responses via a complex exchange of myokines and osteokines signaling between muscle and bone. Because of the growing awareness, consumers prefer doing basic exercises instead of taking medications.

REPORT COVERAGE

  

REPORT METRIC

DETAILS

Market Size Available

2023 to 2029

Base Year

2023

Forecast Period

2024 to 2029

Segments Covered

By Treatment, Route of administration, distribution channel, and Region

Various Analyses Covered

Global, Regional and Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Market Leaders Profiled

Abbott Laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKline plc.

 

SEGMENTAL ANALYSIS

Sarcopenia Treatment Market  Analysis By Treatment Type

The protein supplements segment is expected to dominate the global market during the forecast period. Sarcopenia is associated with progressive loss of skeletal muscles. Proteins are the building blocks of the body. Hence Proteins are a necessary supplement to treat Sarcopenia and increase mobility despite the cost associated with it.The vitamin B12 segment is anticipated to account for a considerable share of the worldwide market during the forecast period. Vitamin B12 is a necessary medication involved in sarcopenia treatment.

Sarcopenia Treatment Market  Analysis By Route of Administration

The oral segment is expected to hold the leading share of the global market during the forecast period. Oral is the simplest and most convenient mode of administration of drugs and supplements, especially for prolonged usage, which is convenient as a treatment for Sarcopenia as the medications and supplements need to be taken regularly. The benefits that the oral route of administration offers are one of the major factors propelling segmental growth. In cases where patients are suffering from Chronic Illnesses or disability due to extreme levels of Sarcopenia, other routes of administration are used.

Gloabal Sarcopenia Treatment Market Analysis By Distribution Channel

The drug stores & retail pharmacies segment is expected to hold the leading share of the worldwide market in the coming years due to the convenience it provides. Consumers can approach the nearest drug stores and retail Pharmacies and buy the supplements and medications in bulk for a whole month. This is particularly convenient for the elderly as most patients of Sarcopenia are elderly and need to take supplements and medications regularly.The online pharmacies segment is predicted to account for a prominent share of the worldwide market during the forecast period. Online stores are slightly gaining market share. The elderly and aged people are not very tech savvy to order from Online Pharmacies despite the convenience it provides.The hospital pharmacies segment is anticipated to hold a considerable share of the global market in the coming years. Hospital pharmacies can be a bit challenging and inconvenient as the requirement for medications and supplements would be constant.

REGIONAL ANALYSIS

The North American region dominated the sarcopenia treatment market in 2023 and the domination is most likely to continue throughout the forecast period. Factors such as the population demographics and a higher number of geriatric and aged populations making them prone to sarcopenia majorly propel the North American market. The sarcopenia patients in the North American region also have expendable resources and with high prices of healthcare, the consumers can also opt for the sarcopenia treatment market for preventive measures.

Europe is growing rapidly and will hold the second-largest share of the global sarcopenia treatment market during the forecast period. The European region is also expected to grow at a healthy CAGR during the forecast period owing to the growing aging population in the European region during the forecast period. Europe also has an excellent healthcare infrastructure and a population with disposable income.

The APAC is predicted to register the highest CAGR in the global sarcopenia treatment market during the forecast period due to rising cases of sarcopenia. The patient population suffering from sarcopenia is growing at an alarming rate in the Asia-Pacific region due to malnutrition. The awareness about sarcopenia in the countries of the Asia-Pacific region has seen a spike in recent times, which favors the APAC market growth.

Latin America and the Middle East & Africa are expected to be at a steady growth rate in the global sarcopenia treatment market during the forecast period.

KEY PLAYERS IN THE GLOBAL SARCOPENIA TREATMENT MARKET

Abbott Laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKline plc., Nestle S.A., Pfizer, Inc., Novartis AG, Sanofi, Inc., Zydus Cadila, Ltd and F-Hoffmann La-Roche are some of the major players in the global sarcopenia treatment market.

RECENT HAPPENINGS IN THE MARKET

  • In 2023, in a new research paper on Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 5, entitled, "AAV1.NT-3 gene therapy prevents age-related sarcopenia”. In this new study by researchers from Nationwide Children's Hospital and Ohio State University, it was found that the AAV1.NT-3 Gene therapy can help prevent age-related Sarcopenia during their tests on wild-aged mice. This research is still in its early stages and holds a lot of promise to present a definitive preventive measure for Age-related Sarcopenia.

  • In July 2023, Biophytis, an SA-based clinical-stage biotechnology company, filed for approval from the US Food and Drug Administration (FDA) to launch its SARA-31, which is the first-ever Phase III study in sarcopenia. SARA-31 is expected to evaluate the efficacy and safety of Sarconeos (BIO101) their Lead Drug Candidate in treating sarcopenic patients at risk of mobility disability.

DETAILED SEGMENTATION OF GLOBAL SARCOPENIA TREATMENT MARKET INCLUDED IN THIS REPORT

The research report on the sarcopenia treatment market has been segmented and sub-segmented into Treatment, Route of administration, distribution channel, and region.

By Treatment Type

  • Protein Supplements
  • Vitamin B12 Supplements
  • Vitamin D & Calcium Supplements

By Route of Administration

  • Oral
  • Parenteral
  • Enteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa 

Please wait. . . . Your request is being processed

Anil Kumar P is research manager at Market Data Forecast and responsible for Healthcare Domain.

Author

Anil Kumar P (Research Manager - Healthcare)

Anil Kumar P is the lead author of this report and the manager of the team responsible for authoring healthcare reports at Market Data Forecast. He holds a Bachelor’s degree in Pharmacy (Hons.) from BITS Pilani, one of India’s premier institutions. Over the past seven years, Anil has gained extensive experience working with multiple market research companies, where he has collaborated with a diverse range of clients—from innovative startups to Fortune 500 companies—delivering data-driven insights and strategic advice that drive business growth.

Read More

Frequently Asked Questions

What are some key trends driving the sarcopenia treatment market?

Key trends include the rise of personalized medicine, the integration of digital health solutions for remote monitoring and guidance, and the increasing focus on combining multiple treatment approaches for better outcomes.

Are there any challenges hindering market expansion?

Challenges include the lack of standardized diagnostic criteria, limited awareness about sarcopenia among both patients and healthcare providers, and the absence of approved pharmaceutical treatments.

Are there any technological innovations impacting the market?

Yes, wearable devices, telemedicine platforms, and mobile apps are being integrated into treatment strategies, enabling remote monitoring of patients' progress and adherence to exercise regimens.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample